Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia

Leukemia

Volumn 10, Issue 1, 1996, Pages 40-42

  Feldman, E J ^a   Seiter, K P ^a   Ahmed, T ^a   Baskind, P ^a   Arlin, Z A ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Homoharringtonine; Myelodysplastic syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; HOMOHARRINGTONINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CELL DEATH; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; FEMALE; FLUID RETENTION; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; VOMITING;

EID: 0030051722     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Milner GR et al. Bone marrow culture studies in refractory cytopenia and 'smoldering leukemia'. Br J Haematol 1977; 35: 251-261.
2. Second International Workshop on Chromosomes in Leukemia: Chromosomes in preleukemia. Cancer Genet Cytogenet. 1985; 2: 108-194.
3. Cephalotaxus Research Coordinating Group. Cephalotaxine esters in treatment of acute leukemia: a preliminary clinical assessment. Chinese Med J 1975; 2: 263-272.
4. Chinese People's Liberation Army 187th Hospital. Harringtonine in acute leukemias: clinical analysis of 31 cases. Chinese Med J 1977; 3: 319-324.
5. Hematology Research Division and Hematology Section of the Children's Hospital, Suzhou Medical College. High remission induction (traditional Sino-Western HOAP) regimen for acute non-lympholeukemia. Chinese Med J 1980; 93: 565-568.
6. Warrell RP, Coonley CJ, Gee TS. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol 1985; 3: 617-621.
7. Feldman E et al. Homoharringtone is safe and effective for patients with acute myelogenous leukemia. Leukemia 1992; 6: 1185-1188.
8. Stewarat JA, Cassileth PA, Bennett JM, O'Connell MJ. Continuous infusion Homoharringtonine (NSC 141633) in refractory acute non-lymphocytic leukemia. An ECOG pilot study. Am J Clin Oncol 1988; 11: 627-629.
9. Kantarjian HM et al. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 1989; 63: 813-817.
10. Baaske DM, Heinstein P. Cytotoxicity and cell cycle specificity of homoharringtonine. Antimicrob Agents Chemother 1977; 12: 298-300.
11. Boyd AW, Sullivan JR. Leukemic cell differentiation in vivo and in vitro: arrest of proliferative parallels the differentiation induced by the antileukemic drug harringtonine. Blood 1984: 6: 384-392
12. Wang Y, Pan Z, Han R. The cytokinetic effects of harringtonine on leukemia L1210 cells. II. Studies by microscopic photometer. Zhonghua ZaZhi (Chinese with English abstr.) 1980; 2: 247-250.
13. De Witte T, Muus P, De Pauw B, Haanen C. Intensive antileukemic treatment of patients younger than 65 years with myelodysptastic syndromes and secondary acute myelogenous leukemia. Cancer 1990; 66: 831-837.
14. Tricot G, Boogaerets MA. The role of aggressive chemotherapy in the treatment of myelodysplastic syndromes. Br J Haematol 1986, 63: 477-483.
15. Gajewski JL et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemia syndrome J Clin Oncol 1989; 7: 1637-1645.
16. Jing-Song Y et al. Small dose harringtonine induces complete remission in patients with acute promyelocytic leukemia. Leukemia 1988; 2: 427-429.
17. 1) chronic myelogenous leukemia (CML). Blood 1992; 80 (Suppl. 1): 358.
18. O'Brien S et al. Sequential Homoharringtonine (HHT) and interferon (IFN-A) produce high hematological and cytogenetic response rates in Philadelphia chromosome-positive (Ph) chronic myelogenous leukemia (CML). Proc ASCO 1995; 14: 336.